Rivaroxaban gets EU support for use with acute coronary syndrome

The anticoagulant rivaroxaban should be considered for preventive use in patients with acute coronary syndrome, according to a recommendation from the EU's Committee for Medicinal Products for Human Use. The panel's opinion comes weeks after the FDA sought additional information instead of approving a similar indication in the U.S.

View Full Article in:

TheHeart.org (Montreal) (free registration) · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX